Developing novel approaches to treatment of the most aggressive cancers, Tradewind BioScience is a biotechnology company developing antibody therapeutics for ovarian cancer. The firm's lead candidate is a multifaceted attack - an approach that enables targeting primary cancer cells directly, alongside enabling the immune system's natural anti-cancer function, all with one therapeutic antibody.
